News & updates.

Grants, partnerships, and regulatory milestones from Britecyte.

$1M MSCRF grant powers novel adipose allograft therapy for osteoarthritis

$1M grant from the Maryland Stem Cell Research Fund (MSCRF) powers novel adipose tissue allograft therapy for osteoarthritis.

Grant

MSCRF awards $1M clinical grant for BRC-OA knee osteoarthritis study

Britecyte’s Phase 1/2a multicenter study of BRC-OA, a human adipose allograft for knee osteoarthritis, was awarded a $1,000,000 Clinical Program Grant from MSCRF.

Clinical

Britecyte’s adipose tissue allograft earns FDA “Safe to Proceed” status

FDA “safe to proceed” status for BRC-OA marks a significant step toward clinical evaluation in osteoarthritis.

Regulatory

LifeLink Tissue Bank and Britecyte join forces on adipose tissue technology

LifeLink® Tissue Bank and Britecyte® announce a strategic collaboration on recovery, processing, and clinical application of adipose tissue.

Partnership

MSCRF awards $270K commercialization grant for NASH research

Britecyte’s research project on a mesenchymal stem cell–containing matrix for NASH was awarded a $270,000 Commercialization Program Grant from MSCRF.

Grant